Atea Pharma reports Q3 net loss $8.1M; cash $665M; SUNRISE-3 enrollment imminent

Atea Pharmaceuticals, Inc.

2022-Q3 EPS reported -$0.98

Net loss of $8.1M ($0.10 per share) vs net loss of $28.2M in Q3 2021.
Cash and marketable securities $665.0M at Sept 30, 2022, down from $764.4M at Dec 31, 2021.
R&D expenses fell to $4.9M from $43.0M, aided by a $14.5M credit from Roche cost share close-out.
SUNRISE-3 Phase 3 trial for bemnifosbuvir in high-risk COVID-19 patients expected to start enrollment before year-end 2022.
AT-752 human challenge study and DEFEND-2 first cohort completion expected around year-end; HCV trial submission also anticipated.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Atea Pharmaceuticals, Inc. reported financial results for third quarter ended September 30, 2022.

Period: third quarter ended September 30, 2022
Result: reported results

Exact text from the filing

Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today reported financial results for the third quarter ended September 30, 2022

View on SEC.gov

168 earnings releases filed in the last 30 days. Browse all earnings releases →

Atea Pharmaceuticals, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-22-279097

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.